Signs, Symptoms, and Side-Effects Presented by Different Types of COVID-19 Vaccines: A Prospective Cohort Study.

COVIran Barekat Covaxin Oxford AstraZeneca Sinopharm Sputnik V pandemic

Journal

Life (Basel, Switzerland)
ISSN: 2075-1729
Titre abrégé: Life (Basel)
Pays: Switzerland
ID NLM: 101580444

Informations de publication

Date de publication:
07 Dec 2022
Historique:
received: 25 10 2022
revised: 27 11 2022
accepted: 05 12 2022
entrez: 23 12 2022
pubmed: 24 12 2022
medline: 24 12 2022
Statut: epublish

Résumé

The concern about post-COVID-19 vaccine complications still remains. In addition, the evidence on Sinopharm, Sputnik V, Covaxin, and, in particular, COVIran Barekat, as well as comparisons between them by dosage after post-vaccination, is scarce. This study aimed to investigate and compare the prevalence of self-reported post-vaccination signs and symptoms following the first and second doses of different types of COVID-19 vaccines. Research design and methods: This prospective cohort study was conducted on more than 1500 health professionals who had received at least one dose of any type of Sputnik V, Sinopharm, Oxford AstraZeneca, Covaxin, and COVIran Barekat vaccines in Iran. The survey questionnaire was sent to participants online, 28 days after receiving each dose of the vaccine. Results: About 73% of health professionals reported at least one post-vaccination sign or symptom, developing mostly within the first 12 h (69.9%) and lasting up to 12 h (59.0%). Pain and tenderness at the injection site, fever, and muscle pain were the most common post-vaccination signs and symptoms in all vaccines, which were significantly higher in the Oxford AstraZeneca vaccine (p < 0.001) for both the first and second doses. The incidence rate of all post-vaccination signs and symptoms was significantly higher in the first dose than in the second dose (p < 0.05). Conclusion: The Oxford AstraZeneca vaccine showed the highest incidence rate, onset, and lasting time of signs and symptoms in both doses; however, they were not life-threatening. The onset time of signs and symptoms was significantly higher for the COVIran Barekat and Oxford AstraZeneca vaccines in both the first and second doses.

Identifiants

pubmed: 36556411
pii: life12122046
doi: 10.3390/life12122046
pmc: PMC9787785
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Sci Rep. 2021 Nov 2;11(1):21464
pubmed: 34728696
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
Pharmaceutics. 2021 Oct 21;13(11):
pubmed: 34834174
Int J Infect Dis. 2021 May;106:376-381
pubmed: 33866000
MMWR Morb Mortal Wkly Rep. 2021 Jan 15;70(2):46-51
pubmed: 33444297
JAMA. 2021 Jun 1;325(21):2201-2202
pubmed: 33818592
Front Public Health. 2022 May 16;10:896343
pubmed: 35651866
Lancet Infect Dis. 2021 Jan;21(1):39-51
pubmed: 33069281
Metabol Open. 2021 Sep;11:100101
pubmed: 34179744
J Clin Med. 2021 Apr 01;10(7):
pubmed: 33916020
Clin Dermatol. 2021 May-Jun;39(3):523-531
pubmed: 34518015
Metabol Open. 2021 Dec;12:100124
pubmed: 34541483
Lancet Infect Dis. 2021 Jul;21(7):939-949
pubmed: 33930320
J Multidiscip Healthc. 2021 Sep 16;14:2577-2585
pubmed: 34556992
Biochim Biophys Acta Mol Basis Dis. 2020 Oct 1;1866(10):165878
pubmed: 32544429
Prehosp Disaster Med. 2021 Oct;36(5):659-660
pubmed: 34287113
Vaccines (Basel). 2021 May 26;9(6):
pubmed: 34073382
Int J Biol Macromol. 2021 Oct 1;188:740-750
pubmed: 34403674
Int J Infect Dis. 2021 Oct;111:219-226
pubmed: 34384899
Int Immunopharmacol. 2021 Dec;101(Pt B):108351
pubmed: 34801416
Biology (Basel). 2021 Aug 05;10(8):
pubmed: 34439984
Lancet. 2021 Jan 30;397(10272):355-357
pubmed: 33453149
Arch Med Res. 2021 May;52(4):456-457
pubmed: 33483149

Auteurs

Zahra Zare (Z)

Department of Midwifery, School of Nursing and Midwifery, Sabzevar University of Medical Sciences, Sabzevar 9617213112, Iran.

Abdolghader Assarroudi (A)

Iranian Research Center on Healthy Aging, Department of Medical-Surgical Nursing, School of Nursing and Midwifery, Sabzevar University of Medical Sciences, Sabzevar 9617213112, Iran.

Mohammad Reza Armat (MR)

Geriatric Care Research Center, Department of Medical-Surgical Nursing, School of Nursing and Midwifery, North Khorasan University of Medical Sciences, Bojnurd 7487794149, Iran.

Mojtaba Laal Ahangar (M)

Sheffeild Teaching Hospital, Sheffeild S5 7AU, UK.

Mahdie Estaji (M)

Department of Midwifery, School of Nursing and Midwifery, Mashhad University of Medical Sciences, Mashhad 9137913199, Iran.

Vahideh MoghaddamHosseini (V)

Iranian Research Center on Healthy Aging, Department of Midwifery, School of Nursing, University of Medical Sciences, Sabzevar 9617213112, Iran.

Mostafa Dianatinasab (M)

Department of Complex Genetics and Epidemiology, School of Nutrition and Translational Research in Metabolism, Maastricht University, 6228 GR Maastricht, The Netherlands.

Classifications MeSH